MindWalk (HYFT) Q1 2027 earnings summary
Event summary combining transcript, slides, and related documents.
Q1 2027 earnings summary
14 Sep, 2026Executive summary
Launched ReefIQ, a proprietary data platform for structuring complex biological data to drive AI-enabled drug discovery, focusing on enterprise adoption and multi-year recurring revenue relationships.
Revenue grew 21.3% year-over-year to $3.8 million, driven by the commercial launch of ReefIQ and a shift toward recurring, platform-based revenue.
Net loss from continuing operations widened to $6.1 million ($0.13 per share) from $4.1 million ($0.09 per share), reflecting planned investments in commercial infrastructure for ReefIQ.
Achieved a key infrastructure milestone by validating OpenFold3 deployment on AMD Instinct MI325X GPUs, enhancing scalability and discovery capabilities.
Internal pipeline advancing through preclinical development, with new leadership added to accelerate IND-enabling work.
Financial highlights
Revenue for Q1 FY2027 was $3.8 million, up 21.3% year-over-year from $3.2 million, marking five consecutive quarters of growth.
Gross margin expanded to 59% from 48% year-over-year, reaching $2.2 million.
Net loss from continuing operations was $6.1 million, compared to $4.1 million in the prior year; prior year net loss included $1.1 million income from discontinued operations.
Sales and marketing expenses increased to $3.2 million from $1.3 million, reflecting planned investments in commercial infrastructure.
Cash balance at quarter-end was $7.6 million, with net cash used in operating activities at $4 million.
Outlook and guidance
Revenue expected to remain lumpy in the near term due to milestone-based nature of initial ReefIQ agreements; recurring revenue to increase as contracts mature.
No specific timeline provided for closing major ReefIQ agreements, but management has strong visibility and confidence in ongoing negotiations.
Commercial model is shifting to recurring, compounding revenue centered on ReefIQ.
$30 million unsecured revolving credit facility commitment provides flexibility to fund enterprise onboarding and platform partnerships.
Latest events from MindWalk
- Recurring data platform, revenue growth, and enterprise adoption drive compounding value.HYFT
Investor presentation - AI-driven biologics innovator launches $50M ATM share offering to fund R&D and growth initiatives.HYFT
Registration filing - Revenue up 46%, gross margin at 59%, net loss per share improved, and recurring SaaS revenue booked.HYFT
Q4 2026 - AI-driven life sciences platform seeks up to $250M for R&D and growth, leveraging patented HYFT® technology.HYFT
Registration filing - Q3 revenue up 52% to $4.2M, recurring LensAI contract signed, and cash reached $14.2M.HYFT
Q3 2026 - Record revenue, margin gains, and BioStrand growth drive AI-focused momentum.HYFT
Q4 2025 - Gross margin rose to 56% as AI focus grows, but liquidity and Nasdaq risks persist.HYFT
Q2 2025 - Revenue fell 7.5% to CAD 5.3M, net loss widened, and urgent funding needs persist.HYFT
Q1 2025 - Record revenue and AI-driven growth offset by impairment-related net loss in FY 2024.HYFT
Q4 2024